VistaGen Therapeutics, Inc. (VTGN)

NASDAQ: VTGN · IEX Real-Time Price · USD
0.120
-0.011 (-8.46%)
Dec 7, 2022 4:00 PM EST - Market closed
-8.46%
Market Cap 25.75M
Revenue (ttm) -185,600
Net Income (ttm) -64.69M
Shares Out 206.81M
EPS (ttm) -0.34
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 9,199,575
Open 0.13
Previous Close 0.131
Day's Range 0.116 - 0.133
52-Week Range 0.08 - 2.11
Beta 0.50
Analysts Buy
Price Target 0.23 (+91.5%)
Earnings Date Nov 10, 2022

About VTGN

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder... [Read more]

Industry Biotechnology
Founded 1998
Employees 34
Stock Exchange NASDAQ
Ticker Symbol VTGN
Full Company Profile

Financial Performance

In 2021, VTGN's revenue was $1.11 million, an increase of 1.78% compared to the previous year's $1.09 million. Losses were -$47.76 million, 166.3% more than in 2020.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for VTGN stock is "Buy." The 12-month stock price forecast is 0.23, which is an increase of 91.51% from the latest price.

Price Target
$0.23
(91.51% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Vistagen Receives FDA Fast Track Designation for Development of PH10 to Treat Major Depressive Disorder

SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, d...

1 day ago - Business Wire

Vistagen Receives FDA “Study May Proceed” Letter Under its Investigational New Drug Application for PH10 to Treat Maj...

SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Vistagen, (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, ...

1 week ago - Business Wire

Vistagen Announces Publication in Cells Demonstrating AV-101's Potential for Treating Levodopa-Induced Dyskinesia in ...

SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, d...

2 weeks ago - Business Wire

What Makes VistaGen Therapeutics, Inc. (VTGN) a New Buy Stock

VistaGen Therapeutics, Inc. (VTGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

3 weeks ago - Zacks Investment Research

VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates

VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of 0% and 388.07%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the st...

3 weeks ago - Zacks Investment Research

Vistagen Reports Second Quarter Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, ...

3 weeks ago - Business Wire

Vistagen to Present at Stifel 2022 Healthcare Conference

SOUTH SAN FRANCISCO, Calif.

1 month ago - Business Wire

Vistagen Announces the Two Leading Proxy Advisory Firms, Institutional Shareholder Services and Glass Lewis, Recommen...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen Therapeutics, Inc. (Nasdaq: VTGN) (the Company), a late clinical-stage biopharmaceutical company aiming to transform the tr...

2 months ago - Business Wire

Vistagen to Participate at Cantor Neurology & Psychiatry Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals...

2 months ago - Business Wire

Vistagen CEO Shawn Singh to Join Executive Roundtable Discussing Mental Health at Concordia Annual Summit

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals...

2 months ago - Business Wire

Vistagen Presents Poster at Psych Congress 2022 Highlighting Effect of PH94B on Nasal Electrogram Responses and Bioma...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals livi...

2 months ago - Business Wire

Vistagen to Participate in Upcoming Morgan Stanley and Baird Healthcare Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen to Participate in Fireside Chats at Morgan Stanley and Baird Healthcare Conferences

2 months ago - Business Wire

Vistagen to Proceed with PALISADE-2 Phase 3 Clinical Trial of PH94B in Social Anxiety Disorder following Interim Anal...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen's PALISADE-2 clinical trial to resume after interim analysis by independent biostatisticians recommends continuation withou...

2 months ago - Business Wire

VistaGen Therapeutics Reports First Quarter Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--VistaGen Therapeutics Reports First Quarter Financial Results and Provides Corporate Update

3 months ago - Business Wire

VistaGen Therapeutics to Report Fiscal Year 2023 First Quarter Financial Results on August 11, 2022

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--VistaGen Therapeutics, Inc. (NASDAQ: VTGN) a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living wit...

3 months ago - Business Wire

VistaGen Therapeutics (VTGN) Stock Plunges on Disappointing Clinical Data

VistaGen Therapeutics (VTGN) stock is falling hard on Friday after the company reported poor results from a Phase 3 study. The post VistaGen Therapeutics (VTGN) Stock Plunges on Disappointing Clinical D...

4 months ago - InvestorPlace

VistaGen Announces Topline Results from PALISADE-1 Phase 3 Clinical Trial for Investigational Drug PH94B

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen, the Company), a late clinical-stage biopharmaceutical company aiming to transform the treatment landsc...

4 months ago - Business Wire

VistaGen CEO Joins U.S. Surgeon General to Discuss Mental Health Crisis in America at the 2022 Concordia Americas Summit

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--VistaGen's CEO will join U.S. Surgeon General, Vice Admiral Vivek H. Murthy at the Concordia Summit to discuss the ongoing mental he...

4 months ago - Business Wire

VistaGen to Participate at William Blair Biotech Focus Conference 2022

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #PH94B--VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen), a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical compan...

5 months ago - Business Wire

VistaGen Therapeutics, Inc. (VTGN) Reports Q4 Loss, Misses Revenue Estimates

VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of -33.33% and 88.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the st...

5 months ago - Zacks Investment Research

VistaGen Therapeutics Reports Fiscal Year 2022 Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--VistaGen Therapeutics Reports Fiscal Year 2022 Financial Results and Provides Corporate Update

5 months ago - Business Wire

VistaGen Announces Completion of PALISADE-1 Phase 3 Clinical Study of PH94B for the Acute Treatment of Social Anxiety...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #VistaGen--VistaGen announces completion of PALISADE-1 Phase 3 clinical trial of PH94B for the acute treatment of anxiety in adults with social anx...

5 months ago - Business Wire